Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Bayer HealthCare Pharmaceuticals' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Bayer HealthCare Pharmaceuticals' found in 1 term [] and 6 definitions [], (+ 1 Boolean[] results
1 - 5 (of 8)     next
Result Pages : [1]  [2]
MRI Resources 
Cochlear Implant - Veterinary MRI - Quality Advice - Spine MRI - DICOM - Most Wanted
 
Bayer HealthCare PharmaceuticalsMRI Resource Directory:
 - Manufacturers -
 
berlex.bayerhealthcare.com In June 2006 Bayer AG has bought the majority of shares of Schering AG. As a result of this take-over Schering AG has been renamed in December 2006 in Bayer Schering Pharma AG. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
Berlex Laboratories (USA) and Berlex Canada Inc., former affiliates of Schering AG, have been integrated into Bayer HealthCare and operate as a specialty pharmaceuticals business that also sells MRI contrast agents, under the name Bayer HealthCare Pharmaceuticals, which is a subsidiary of Bayer Schering Pharma AG.
Contact Information
MAIL
Bayer HealthCare Pharmaceuticals
Headquarters?
PHONE
+1-888-842-2937
spacer
 
• Share the entry 'Bayer HealthCare Pharmaceuticals':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Bayer HealthCare Pharmaceuticals' (2).Open this link in a new window.
 
Further Reading:
  News & More:
New data presented at RSNA on use of Bayer's Gadavist® (gadobutrol) injection in children less than 2 years of age
Wednesday, 3 December 2014   by www.prnewswire.com    
MRI Resources 
Sequences - General - Pacemaker - Education - Corporations - Devices
 
Berlex Laboratories, Inc.MRI Resource Directory:
 - Manufacturers -
 
www.berleximaging.com [This entry is marked for removal.]

Berlex Laboratories, Inc. was an US affiliate of Schering AG Germany (now Bayer Schering Pharma AG ).
In June 2006 Bayer AG has bought the majority of shares of Schering AG. As a result of this take-over the new formed company has been named Bayer HealthCare Pharmaceuticals.
For contrast agents distributed by Berlex Laboratories, Inc. please see Bayer HealthCare Pharmaceuticals.
spacer

• View the NEWS results for 'Berlex Laboratories, Inc.' (1).Open this link in a new window.
MRI Resources 
Mass Spectrometry - MRCP - Stimulator pool - Spectroscopy pool - Raman Spectroscopy - Used and Refurbished MRI Equipment
 
Endoremâ„¢InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
A brand name for ferumoxide (same as Feridex®)
Endoremâ„¢ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endoremâ„¢ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.

See also Ferumoxide.
Drug Information and Specification
NAME OF COMPOUND
Dextran-coated ferumoxide, Ami-25
CENTRAL MOIETY
Fe2+/Fe3+
CONTRAST EFFECT
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
340 mosm/kgH2O
CONCENTRATION
11.2mg Fe/ml
DOSAGE
15 µmol Fe/kg
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Brazil
Endoremâ„¢
for sale
Argentina
for sale
South Korea
for sale
Israel
for sale
spacer

• View the DATABASE results for 'Endorem™' (5).Open this link in a new window

 
Further Reading:
  News & More:
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
Shoulder MRI - Stent - Cochlear Implant - Corporations - Collections - Databases
 
Gadovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Gadovist® is an extracellular, neutral macrocyclic (gadolinium (Gd) complex) MRI contrast agents for central nervous system indications, particularly suited for studies in which high doses are required or advantageous. Gadovist® (also Gadograf) was available in two concentrations, currently only Gadovist® 1.0 is marketed.
The product was approved in Switzerland in 1999 and in Germany in 2000. Gadovist® 1.0 is in USA currently in the drug development and approval process, particularly for magnetic resonance angiography.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Paramagnetic Contrast Agents and Gadobutrol.
Drug Information and Specification
NAME OF COMPOUND
Gadobutrol, Gd-BT-DO3A
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.6, B0=1.0 T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
OSMOLALITY
557 and 1603 mosm/kgH2O
CONCENTRATION
1 mol/L
DOSAGE
0.1mmol/kg
PREPARATION
Finished product
INDICATION
Central nervous system / whole body
DEVELOPMENT STAGE
For sale / submit for approval
DISTRIBUTOR
See below
PRESENTATION
Vials of 15, 30 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Gadovist®
Submit for approval
Japan
Gadovist®
EU
Gadovist®
for sale
Australia
Gadovist®
for sale
spacer

• View the DATABASE results for 'Gadovist®' (5).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
Gadograf, Gadovist
Friday, 13 April 2007   by www.ema.europa.eu    
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
FDA approves Bayer's Gadavist® (gadobutrol) injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age
Monday, 5 January 2015   by www.prnewswire.com    
New data presented at RSNA on use of Bayer's Gadavist® (gadobutrol) injection in children less than 2 years of age
Wednesday, 3 December 2014   by www.prnewswire.com    
MRI Resources 
Shielding - Fluorescence - Cochlear Implant - MRCP - MRI Training Courses - Diffusion Weighted Imaging
 
Magnevist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® is a paramagnetic ionic contrast agent for use in magnetic resonance imaging. Contrast enhanced MRI with Magnevist® allows additional diagnostic information of tumors, inflammation and vascular lesions and the determination or differentiation of such lesions.
The contrast enhancing effect is produced by the di-N-methylglucamine salt of gadopentetate (Gd-DTPA), the gadolinium complex of diethylenetriamine pentaacetic acid. Magnevist® has the strongest effect on T1 weighted images, by increasing T1 signal intensity in tissues where Magnevist® has accumulated.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Ionic Intravenous Contrast Agents and Gadopentetate Dimeglumine.
Drug Information and Specification
CENTRAL MOIETY
Gd3+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=3.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
1960 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1-0.3 mmol/kg / 0.2-0.6 mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20 and 100 mL bulk package
Pre-filled syringes of 10, 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada
Magnevist®
for sale
Asia
Magnevist®
for sale
EU
Magnevist®
suspended
Turkey
Magnevist®, Magnograf
for sale
Australia
Magnevist®
for sale
spacer

• View the DATABASE results for 'Magnevist®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Magnevist Prescription Drug Discount Sources
   by www.institutedc.org    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection - WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
May 2009   by berlex.bayerhealthcare.com    
Magnevist Package Insert
2000
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
MRI Resources 
Services and Supplies - Devices - Quality Advice - Software - Pregnancy - MRI Technician and Technologist Schools
 
     1 - 5 (of 8)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Personalized protocols (age, gender, body habitus, etc.) lead to :
more automated planning 
improved patient comfort 
better diagnostics 
optimized image quality 
nothing 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]